A Phase I Study of Oral MEK162 in Japanese Patients With Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 22 Mar 2018
At a glance
- Drugs Binimetinib (Primary)
- Indications Malignant melanoma; Solid tumours
- Focus Adverse reactions
- Sponsors Array BioPharma; Novartis
- 20 Mar 2018 Status changed from active, no longer recruiting to completed.
- 22 Dec 2017 Planned End Date changed from 31 Dec 2017 to 31 Dec 2018.
- 10 Jun 2017 Biomarkers information updated
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History